VistaGen Therapeutics, Inc. (VTGN): Price and Financial Metrics


VistaGen Therapeutics, Inc. (VTGN): $0.25

-0.05 (-16.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VTGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VTGN Stock Summary

  • VISTAGEN THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 6.93% of US listed stocks.
  • As for revenue growth, note that VTGN's revenue has grown -112.65% over the past 12 months; that beats the revenue growth of just 0.51% of US companies in our set.
  • In terms of volatility of its share price, VTGN is more volatile than 98.5% of stocks we're observing.
  • Stocks that are quantitatively similar to VTGN, based on their financial statements, market capitalization, and price volatility, are MEIP, SYBX, TCRX, PIRS, and OGEN.
  • VTGN's SEC filings can be seen here. And to visit VISTAGEN THERAPEUTICS INC's official web site, go to www.vistagen.com.

VTGN Valuation Summary

  • VTGN's price/sales ratio is -254.8; this is 5096.08% lower than that of the median Healthcare stock.
  • VTGN's EV/EBIT ratio has moved down 0 over the prior 82 months.

Below are key valuation metrics over time for VTGN.

Stock Date P/S P/B P/E EV/EBIT
VTGN 2023-01-30 -254.8 1.6 -0.7 -0.2
VTGN 2023-01-27 -235.5 1.5 -0.7 -0.2
VTGN 2023-01-26 -213.4 1.3 -0.6 -0.1
VTGN 2023-01-25 -197.8 1.2 -0.6 -0.1
VTGN 2023-01-24 -201.1 1.3 -0.6 -0.1
VTGN 2023-01-23 -198.9 1.2 -0.6 -0.1

VTGN Growth Metrics

    The 5 year cash and equivalents growth rate now stands at -53.61%.
  • Its year over year price growth rate is now at -61.19%.
  • Its 2 year price growth rate is now at 94.39%.
Over the past 49 months, VTGN's revenue has gone down $185,600.

The table below shows VTGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 -0.1856 -59.9431 -64.6911
2022-06-30 1.0649 -55.0519 -60.3775
2022-03-31 1.1089 -45.2565 -48.7075
2021-12-31 1.5119 -34.9499 -61.579
2021-09-30 1.4676 -27.893 -56.4881
2021-06-30 1.4436 -15.4397 -46.9635

VTGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VTGN has a Quality Grade of C, ranking ahead of 36.05% of graded US stocks.
  • VTGN's asset turnover comes in at 0.017 -- ranking 376th of 682 Pharmaceutical Products stocks.
  • SAGE, SVRA, and EDIT are the stocks whose asset turnover ratios are most correlated with VTGN.

The table below shows VTGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.017 1 -4.522
2021-03-31 0.018 1 -3.130
2020-12-31 0.018 1 -2.501
2020-09-30 0.036 1 -2.651
2020-06-30 0.000 NA -3.134
2020-03-31 0.000 NA -3.789

VTGN Price Target

For more insight on analysts targets of VTGN, see our VTGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1.12 (Strong Buy)

VTGN Stock Price Chart Interactive Chart >

Price chart for VTGN

VTGN Price/Volume Stats

Current price $0.25 52-week high $1.79
Prev. close $0.30 52-week low $0.08
Day low $0.25 Volume 12,901,843
Day high $0.34 Avg. volume 7,486,061
50-day MA $0.15 Dividend yield N/A
200-day MA $0.44 Market Cap 51.61M

VistaGen Therapeutics, Inc. (VTGN) Company Bio


VistaGen Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops products for patients with diseases and disorders involving the central nervous system. VistaGen Therapeutics serves customers in the United States.


VTGN Latest News Stream


Event/Time News Detail
Loading, please wait...

VTGN Latest Social Stream


Loading social stream, please wait...

View Full VTGN Social Stream

Latest VTGN News From Around the Web

Below are the latest news stories about VISTAGEN THERAPEUTICS INC that investors may wish to consider to help them evaluate VTGN as an investment opportunity.

Alluring stocks: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 11.11%), Pinterest, Inc. (NYSE:PINS -5.57%)

VTGN has seen its SMA50 which is now 104.73%. In looking the SMA 200 we see that the stock has seen a -34.01%. PINS has seen its SMA50 which is … The post Alluring stocks: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 11.11%), Pinterest, Inc. (NYSE:PINS -5.57%) appeared first on Stocks Equity .

Stock Equity | February 4, 2023

Morning Investor’s Alert: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 7.22%), LogicMark, Inc. (NASDAQ:LGMK 0.54%)

VTGN has seen its SMA50 which is now 97.56%. In looking the SMA 200 we see that the stock has seen a -36.32%. LGMK has seen its SMA50 which is … The post Morning Investor’s Alert: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 7.22%), LogicMark, Inc. (NASDAQ:LGMK 0.54%) appeared first on Stocks Equity .

Stock Equity | February 3, 2023

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

SOUTH SAN FRANCISCO, Calif., February 02, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals, Inc., a privately held drug development company focused on neuropsychiatric and neuroendocrine conditions (Pherin). Vistagen now owns all intellectual property ri

Yahoo | February 2, 2023

Enrapturing stocks: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 8.02%), Ault Alliance, Inc. (AMEX:AULT -1.43%)

VTGN has seen its SMA50 which is now 65.33%. In looking the SMA 200 we see that the stock has seen a -52.40%. AULT has seen its SMA50 which is … The post Enrapturing stocks: VistaGen Therapeutics, Inc. (NASDAQ:VTGN 8.02%), Ault Alliance, Inc. (AMEX:AULT -1.43%) appeared first on Stocks Equity .

Stock Equity | January 31, 2023

Indicators from Technical Perspective: VistaGen Therapeutics, Inc. (NASDAQ:VTGN -2.78%), Muscle Maker, Inc. (NASDAQ:GRIL 0.42%)

VTGN has seen its SMA50 which is now 48.79%. In looking the SMA 200 we see that the stock has seen a -57.16%. GRIL has seen its SMA50 which is … The post Indicators from Technical Perspective: VistaGen Therapeutics, Inc. (NASDAQ:VTGN -2.78%), Muscle Maker, Inc. (NASDAQ:GRIL 0.42%) appeared first on Stocks Equity .

Stock Equity | January 30, 2023

Read More 'VTGN' Stories Here

VTGN Price Returns

1-mo 53.75%
3-mo 107.30%
6-mo 46.28%
1-year -83.33%
3-year -66.00%
5-year -78.99%
YTD 142.72%
2022 -94.72%
2021 0.52%
2020 181.28%
2019 -54.02%
2018 35.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7844 seconds.